Insider Trading activities of Akebia Therapeutics, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Akebia Therapeutics, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Akebia Therapeutics, Inc. since year 2005. Table 2 shows the detailed insider transactions of Akebia Therapeutics, Inc. since 2005. The reporting company's ticker symbol is AKBA. The reporting company's CIK number is 1517022.
The total value of stock buying since 2005 is $27,412,382.
The total value of stock sales since 2005 is $889,966.
The total value of stock option exercises since 2005 is $105,985.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Akebia Therapeutics, Inc. (AKBA).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-10 0 $0 10,389 $205,248 0 $0
2017-09 0 $0 5,000 $96,500 0 $0
2017-08 0 $0 5,000 $75,000 0 $0
2017-07 1,034,482 $14,999,989 3,943 $56,229 0 $0
2017-04 0 $0 3,948 $36,257 0 $0
2017-01 0 $0 5,419 $56,787 20,000 $9,400
2016-10 0 $0 4,938 $44,223 0 $0
2016-07 0 $0 4,939 $36,912 0 $0
2016-04 0 $0 2,957 $27,824 0 $0
2016-01 0 $0 1,811 $22,239 25,000 $11,750
2015-10 0 $0 2,480 $21,477 0 $0
2015-07 0 $0 2,480 $23,649 0 $0
2015-05 0 $0 0 $0 50,000 $23,500
2015-04 420,000 $3,465,000 2,479 $22,528 0 $0
2015-03 0 $0 0 $0 100,000 $47,000
2015-01 0 $0 2,710 $31,058 0 $0
2014-12 8,000 $94,404 11,933 $134,035 0 $0
2014-11 53,300 $704,464 0 $0 30,500 $14,335
2014-03 479,325 $8,148,525 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Akebia Therapeutics, Inc. insiders (AKBA)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-10-02 Dahan Michel (SVP, Chief Business Officer) Sale 1,398 19.64 27,456
2017-10-02 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 7,803 19.80 154,460
2017-10-02 Nash Duane Sale 1,188 19.64 23,332
2017-09-28 Dahan Michel (SVP, Chief Business Officer) Sale 5,000 19.30 96,500
2017-08-15 Dahan Michel (SVP, Chief Business Officer) Sale 5,000 15.00 75,000
2017-07-05 Satter Muneer A (Director) Buy 1,034,482 14.50 14,999,989
2017-07-03 Dahan Michel (SVP, Chief Business Officer) Sale 1,399 14.26 19,946
2017-07-03 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 1,554 14.26 22,156
2017-07-03 Nash Duane Sale 990 14.27 14,127
2017-04-03 Dahan Michel (SVP, Chief Business Officer) Sale 1,401 9.18 12,858
2017-04-03 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 1,556 9.18 14,280
2017-04-03 Nash Duane Sale 991 9.20 9,119
2017-01-19 Butler John P. (CEO and President) Option Ex 20,000 .47 9,400
2017-01-03 Nash Duane Sale 1,980 10.46 20,710
2017-01-01 Dahan Michel (SVP, Chief Business Officer) Sale 1,629 10.49 17,089
2017-01-01 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 1,810 10.49 18,988
2016-10-03 Nash Duane Sale 1,981 8.96 17,745
2016-10-01 Dahan Michel (SVP, Chief Business Officer) Sale 1,401 8.96 12,545
2016-10-01 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 1,556 8.96 13,933
2016-07-06 Nash Duane Sale 1,980 7.48 14,818
2016-07-05 Dahan Michel (SVP, Chief Business Officer) Sale 1,402 7.47 10,468
2016-07-05 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 1,557 7.47 11,626
2016-04-04 Dahan Michel (SVP, Chief Business Officer) Sale 1,401 9.41 13,183
2016-04-04 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 1,556 9.41 14,641
2016-01-15 Butler John P. (CEO and President) Option Ex 25,000 .47 11,750
2016-01-04 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 1,811 12.28 22,239
2015-10-02 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 1,484 8.67 12,860
2015-10-02 Nash Duane (Director) Sale 996 8.65 8,617
2015-07-02 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 1,484 9.54 14,160
2015-07-02 Nash Duane (Director) Sale 996 9.53 9,489
2015-05-26 Butler John P. (CEO and President) Option Ex 50,000 .47 23,500
2015-04-22 Satter Muneer A (Director) Buy 420,000 8.25 3,465,000
2015-04-02 Hadas Nicole R. (SVP, General Counsel, Sec.) Sale 1,483 9.09 13,477
2015-04-02 Nash Duane (Director) Sale 996 9.09 9,051
2015-03-09 Butler John P. (CEO and President) Option Ex 100,000 .47 47,000
2015-01-02 Hadas Nicole R. (VP General Counsel & Secretary) Sale 1,715 11.46 19,655
2015-01-02 Nash Duane (Director) Sale 995 11.46 11,403
2014-12-29 Butler John P. (CEO and President) Buy 1,000 11.57 11,567
2014-12-26 Nash Duane (Director) Sale 5,169 11.19 57,846
2014-12-24 Nash Duane (Director) Sale 6,764 11.26 76,189
2014-12-22 Butler John P. (CEO and President) Buy 1,000 11.92 11,916
2014-12-15 Butler John P. (CEO and President) Buy 1,000 11.34 11,336
2014-12-02 Renaud Ronald C Jr (Director) Buy 5,000 11.92 59,585
2014-11-26 Amello Jason (SVP, CFO & Treasurer) Buy 1,000 13.22 13,220
2014-11-25 Satter Muneer A (Director) Buy 5,000 13.18 65,900
2014-11-24 Satter Muneer A (Director) Buy 5,000 13.88 69,400
2014-11-21 Satter Muneer A (Director) Buy 5,000 14.73 73,650
2014-11-20 Satter Muneer A (Director) Buy 5,000 14.70 73,500
2014-11-19 Satter Muneer A (Director) Buy 5,000 14.85 74,250
2014-11-18 Satter Muneer A (Director) Buy 5,000 13.84 69,200
2014-11-17 Satter Muneer A (Director) Buy 5,000 12.94 64,700
2014-11-14 Satter Muneer A (Director) Buy 5,000 11.91 59,550
2014-11-13 Satter Muneer A (Director) Buy 5,000 11.56 57,800
2014-11-13 Gowen Maxine (Director) Buy 1,300 11.82 15,364
2014-11-12 Butler John P. (CEO and President) Buy 1,000 10.30 10,305
2014-11-12 Satter Muneer A (Director) Buy 5,000 11.53 57,625
2014-11-11 Butler John P. (CEO and President) Option Ex 30,500 .47 14,335
2014-03-25 Hadas Nicole R. (See Remarks) Buy 3,500 17.00 59,500
2014-03-25 Butler John P. (President and CEO) Buy 13,850 17.00 235,450
2014-03-25 Amello Jason (SVP, CFO & Treasurer) Buy 4,000 17.00 68,000
2014-03-25 Novo A/s (Other) Buy 182,590 17.00 3,104,030
2014-03-25 Satter Muneer A (Director) Buy 91,295 17.00 1,552,015
2014-03-25 Novartis Bioventures Ltd (10% Owner) Buy 182,590 17.00 3,104,030
2014-03-25 Wyzga Michael S (Director) Buy 1,500 17.00 25,500

Insider trading activities including stock purchases, stock sales, and option exercises of AKBA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Akebia Therapeutics, Inc. (symbol AKBA, CIK number 1517022) see the Securities and Exchange Commission (SEC) website.